Abstract
Purpose :
To report the safety and efficacy of conjunctival contact type drug delivery device for latanoprost using hyaluronic acid (HA) as a carrier
Methods :
A tablet of freeze-dry of HA was loaded with latanoprost using ethanol as a solvent. The concentration of loaded latanoprost was verified using high performance liquid chromatography (HPLC). The time needed for complete dissolution of latanoprost containing HA tablet was measured on the living mouse (C57Black6) cornea. When considering the fornix volume of mouse as 5 microliter, commercial latanoprost eyedrop (0.005%) for glaucoma medication contains 0.25 microgram of latanoprost. HA latanoprost tablet was formulated to contain 0.25 microgram of latanoprost in a 1mg of tablet. Total 20 mice were divided in to 4 groups (n=5, each group). Normal saline (group 1), xalatan (group 2), control HA tablet (group 3), and latanoprost HA tablet (group 4) were administered to the right eyes of mice. The left eyes were used as no-treatment control. Intraocular pressure (IOP) of mice were monitored for 10 days. The degree of irritation of mouse was measured by confirming the motion of scratching the left eyes by forelimb for 5 minutes after the application of treatment. Murine eyes were harvested for histologic examination at day 11.
Results :
HA tablet (35mg) was loaded with 8.75 microgram of latanoprost. The yield ratio of latanoprost released from HA tablet was measured by HPLC as 99% with little loss of latanoprost during manufacturing. IOP measured in group 3 and 4 were significantly lower than the other groups. Of note, IOPs in group 4 were significantly lower from day 3 to day 10 compare to group 3. Irritation was measured the least in group 4 compared to the other groups. Histologic examination of murine eyes revealed no significant difference between the groups.
Conclusions :
Freeze-dry of HA loaded with latanoprost proved to safe and effective to deliver medication on murine ocular surface.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.